Soumya Eswaran
3 min read
In This Article:
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate, which increased by 1.76%, outperformed all sectors both absolutely and relatively. The only other sector delivering positive returns was consumer staples, which rose by 0.67%. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as Protagonist Therapeutics, Inc. (NASDAQ:PTGX). Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company. The one-month return of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was 2.86%, and its shares gained 50.15% of their value over the last 52 weeks. On May 23, 2025, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stock closed at $45.66 per share with a market capitalization of $2.83 billion.
Carillon Eagle Small Cap Growth Fund stated the following regarding Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in its Q1 2025 investor letter:
"Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a leading biotechnology company focused on developing drugs for rare and preventable diseases. The company has two key assets: rusfertide for the treatment of polycythemia vera (a type of blood cancer) and icotrokinra for the treatment of psoriasis and ulcerative colitis. During the first quarter, a major pharmaceutical company announced that icotrokinra met its primary endpoint in a phase 2 trial in patients with ulcerative colitis, achieving a clinical remission rate that is among the highest for oral therapies addressing this condition. This positive outcome contributed to the strong performance in the stock."
A research scientist wearing a lab coat working with precision in a biopharmaceutical laboratory.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held Protagonist Therapeutics, Inc. (NASDAQ:PTGX) at the end of the first quarter, which was 37 in the previous quarter. While we acknowledge the potential of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
